Industry News (Patents and Technology)

Oragen Drugs Have Potential To Become The First Broad Spectrum Treatment

Published in Hepatitis Weekly, June 2nd, 1997

HEMISPHERx Biopharma, Inc., Philadelphia, Pennsylvania, announced the receipt of the 300th patent to which HEMX has exclusive rights in the area of treating devastating chronic viral diseases including chronic fatigue syndrome (CFS), hepatitis B (hep B), and HIV infections.

Termed Oragen drugs, the compounds are low molecular weight RNA designer drugs which the company believes have the potential to become the first oral, broad-spectrum treatment for various major viral diseases. In some parts of the world, more than 20 percent of the populations are infected with these diseases. Results from in vitro studies conducted in collaboration with the National Institute of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1997-06-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry